Holen Sie sich die Stockscreener-App
36.23
0.60%
-0.2192
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$36.45
Offen:
$36.39
24-Stunden-Volumen:
1.63M
Relative Volume:
1.11
Marktkapitalisierung:
$3.50B
Einnahmen:
$610.16M
Nettoeinkommen (Verlust:
$-532.93M
KGV:
-6.5532
EPS:
-5.5287
Netto-Cashflow:
$-442.30M
1W Leistung:
+8.25%
1M Leistung:
+18.29%
6M Leistung:
-2.18%
1J Leistung:
-26.54%
1-Tages-Spanne:
$35.68
$36.71
1-Wochen-Bereich:
$33.48
$39.89
52-Wochen-Spanne:
$25.81
$50.00
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
36.23 | 3.52B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap UpTime to Buy? - MarketBeat
Norges Bank Invests $35.77 Million in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Holdings Boosted by Hsbc Holdings PLC - MarketBeat
Is Ultragenyx Pharmaceutical Inc. stock near bottom after declineJuly 2025 Recap & Safe Investment Capital Preservation Plans - Newser
Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Sands Capital Management LLC - MarketBeat
Schroder Investment Management Group Acquires 71,888 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Will Ultragenyx Pharmaceutical Inc. (UP0) stock attract long term capital inflowsLong Setup & Expert Verified Movement Alerts - Newser
Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight - Yahoo Finance Singapore
RARE: Phase 3 data in rare diseases and gene therapy filings are set to drive growth this year - TradingView
Skandinaviska Enskilda Banken AB publ Has $2.46 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Capital Fund Management S.A. Buys 43,903 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 03 - marketscreener.com
Loomis Sayles & Co. L P Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Can Ultragenyx Pharmaceutical Inc. (UP0) stock surprise with quarterly resultsJuly 2025 Breakouts & Daily Volume Surge Signals - Newser
Legal & General Group Plc Purchases 54,837 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Will Ultragenyx Pharmaceutical Inc. (UP0) stock hit Wall Street targets2025 Valuation Update & Precise Buy Zone Tips - Newser
Franklin Resources Inc. Decreases Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ultragenyx (RARE): Assessing Valuation as Revenue Growth and Clinical Progress Fuel Renewed Investor Interest - Yahoo Finance
Ultragenyx Shares Rally After FDA Updates Are They Priced Right for 2025? - Yahoo Finance
Ultragenyx Pharmaceutical (RARE): Evaluating Valuation After Analyst Commentary on Setrusumab Progress and Growth Outlook - Sahm
Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook - MSN
Ultragenyx to Participate in Investor Conferences in December - Sahm
Rhenman & Partners Asset Management AB Grows Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Bear Alert: Will Ultragenyx Pharmaceutical Inc. stock see PE expansion2025 Earnings Surprises & Low Risk Entry Point Tips - BỘ NỘI VỤ
Is Ultragenyx Pharmaceutical Inc. stock positioned well for digital economyTake Profit & Accurate Entry/Exit Alerts - moha.gov.vn
Why Ultragenyx Pharmaceutical Inc. stock is favored by top institutionsNew Guidance & Daily Chart Pattern Signal Reports - moha.gov.vn
Barclays Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $3.28 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by Geode Capital Management LLC - MarketBeat
Barclays Maintains Ultragenyx Pharmaceutical (RARE) Overweight Recommendation - Nasdaq
Ultragenyx (NASDAQ: RARE) to join Citi, Evercore healthcare investor conferences - Stock Titan
RARE: Barclays Lowers Price Target Amid Maintaining Overweight R - GuruFocus
Connor Clark & Lunn Investment Management Ltd. Lowers Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Pharma stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Australia
Ultragenyx (NASDAQ: RARE) grants 18,180 RSUs to 12 non-executive hires - Stock Titan
Is Ultragenyx Pharmaceutical Inc. (UP0) stock a defensive play amid uncertaintyPortfolio Update Report & AI Enhanced Execution Alerts - newser.com
Ultragenyx And Mereo BioPharma: Considering Their Brittle Bone Disease Phase 3 Trials' Prospect - Seeking Alpha
Will Ultragenyx Pharmaceutical Inc. stock reach all time highs in 20252025 AllTime Highs & Growth Focused Entry Reports - newser.com
Can Ultragenyx Pharmaceutical Inc. stock maintain operating margins2025 EndofYear Setup & Verified Chart Pattern Signals - newser.com
Why Ultragenyx Pharmaceutical Inc. stock remains on watchlistsQuarterly Portfolio Review & AI Powered Trade Plan Recommendations - newser.com
Key metrics from Ultragenyx Pharmaceutical Inc.’s quarterly dataJuly 2025 Big Picture & Low Risk High Win Rate Stock Picks - newser.com
Is Ultragenyx Pharmaceutical Inc. still worth holding after the dipTrade Analysis Summary & Weekly Stock Breakout Alerts - newser.com
OMERS increases stake in Ultragenyx’s rare disease drug revenues - Canadian Lawyer Magazine
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):